Jamieson is pleased to announce that it has advised the management team of Catalent, Inc., the global leader in enabling pharma, biotechnology, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, on its $16.5 billion take-private by Novo Holdings.<\/p>\n
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 80 billion doses of nearly 8,000 products annually. Its rapidly growing expert workforce exceeds 18,000, including more than 3,000 scientists and technicians. The company is headquartered in Somerset, New Jersey.<\/p>\n
Mike Sirkin<\/a>,\u00a0Mark Wasserberger<\/a>,\u00a0Ian Rosamilia<\/a>, and\u00a0Barath Mahesh<\/a>\u00a0advised Alessandro Maselli (CEO) and his management team on their reinvestment into the new structure and the terms of the new MIP.<\/p>\n Jamieson Corporate Finance US, LLC is a member of FINRA\/SIPC<\/p>\n","protected":false},"featured_media":5064,"template":"","deal-size":[81],"deal-location":[20],"deal-sector":[48],"deal-service":[91],"class_list":["post-5066","deals","type-deals","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n